Fourth, we excluded studies that used IFN-based agents for non-respiratory infections, leading to exclusion of dozens of studies on multiple sclerosis and hepatitis or on the use of TLRs as adjuvants for vaccines. The gene discussed is IFNA1; the disease is respiratory tract infectious disorder.